Medical management of patients with esophageal or supraesophageal gastroesophageal reflux disease

American Journal of Medicine

Volumn 115, Issue 3 SUPPL. 1, 2003, Pages 179-187

  Richter, Joel E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

COMPARATIVE STUDY; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG RESPONSE; DRUG SAFETY; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SURGERY; GENETIC VARIABILITY; HEALING; HELICOBACTER PYLORI; HUMAN; MEAL; PHYSIOLOGY; PREGNANCY; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME;

EID: 0042158573     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(03)00221-3     Document Type: Conference Paper

References (40)

1. Hatlebakk J.G., Katz P.O., Castell D.O. Medical therapy management of the refractory patients . Gastroenterol Clin North Am. 28:1999;847-860.
2. Kahrilas P.J., Falk G.W., Johnson D.A., et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients a randomized controlled trial . Aliment Pharmacol Ther. 14:2000;1249-1258.
3. Richter J.E., Kahrilas P.J., Johanson J., et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis a randomized controlled trial . Am J Gastroenterol. 96:2001;656-665.
4. Castell D.O., Kahrilas P.J., Richter J.E., et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 97:2002;575-583.
5. Richter J.E., Bochenek W. Oral pantoprazole for erosive esophagitis a placebo-controlled, randomized clinical trial . Am J Gastroenterol. 95:2000;3071-3080.
6. Barrison A.F., Jarbre L.A., Weinberg M.D., et al. Patterns of proton pump inhibitor use in clinical practice. Am J Med. 111:2001;469-473.
7. Vakil N, Kahrilas P, Magner D, et al. Does baseline H. pylori status impact erosive esophagitis healing rates [abstract]? Am J Gastroenterol. 2000;95:2483A.
8. Peghini P.L., Katz P.O., Bracy N.A., Castell D.O. Nocturnal recovery of gastric acid secretion with twice-daily dosing of PPIs. Am J Gastroenterol. 93:1998;763-767.
9. Peghini P.L., Katz P.O., Castell D.O. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole a controlled study in normal subjects . Gastroenterology. 115:1998;1335-1339.
10. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 122:2002;625-632.
11. 2-receptor antagonists. Dig Dis Sci. 35:1990;976-983.
12. Bonavina L., DeMeester T.R., McChesney L., et al. Drug-induced esophageal strictures. Ann Surg. 206:1987;178-183.
13. Champion G., Richter J.E., Vaezi M.F., et al. Duodenogastroesophageal reflux relationship to pH and importance in Barrett's esophagus . Gastroenterology. 107:1994;747-754.
14. Collen M.J., Abdulian J.D., Chen Y.K. Gastroesophageal reflux disease in the elderly more severe disease that requires aggressive therapy . Am J Gastroenterol. 90:1995;1053-1057.
15. Richter J.E. Gastroesophageal reflux disease in the older patient presentation, treatment and complications . Am J Gastroenterol. 95:2000;368-373.
16. Zimmerman A., Walters J.K., Katona B., et al. Alternative methods of proton pump inhibitor administration. The Consultant Pharmacist. 9:1997;990-998.
17. Broussard C.N., Richter J.E. Treating gastro-oesophageal reflux disease during pregnancy and lactation. Drug Saf. 19:1998;325-337.
18. Larson J.P., Patatanian E., Miner P.B., et al. Double-blind, placebo-controlled study of ranitidine for gastroesophageal symptoms during pregnancy. Obstet Gynecol. 90:1997;83-87.
19. Moore J., Flynn R.J., Sampaio M., et al. Effect of single dose omeprazole on intragastric acidity and volume during obstetric anaesthesia. Anaesthesia. 48:1993;114-119.
20. DeVault K.R., Castell D.O. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 94:1999;1434-1442.
21. Carlsson R., Dent J., Watts R., et al. Gastroesophageal reflux disease in primary care an international study of different treatment strategies with omeprazole . Eur J Gastroenterol Hepatol. 10:1998;119-124.
22. Katz P.O., Castell D.O. Approach to the patient with unexplained chest pain. Am J Gastroenterol. 95:(suppl 8):2000;S4-S8.
23. Harding S.M., Sontag S.J. Asthma and gastroesophageal reflux. Am J Gastroenterol. 95:(suppl 8):2000;S23-S32.
24. Wong R.K., Hanson D.G., Waring P.J., Shaw G. ENT manifestations of gastroesophageal reflux. Am J Gastroenterol. 95:(suppl 8):2000;S15-S22.
25. Hauas T., Huang S., Levy M., et al. Posterior laryngitis: double-blind randomised placebo controlled study of proton pump inhibitor therapy. Aust J Otolaryngol. 3:1999;243-246.
26. El-Serag H.B., Lee P., Buchner A., et al. Lansoprazole treatment of patients with chronic idiopathic laryngitis a placebo controlled trial . Am J Gastroenterol. 96:2001;979-983.
27. Ours T.M., Kavuru M.S., Schilz R., Richter J.E. A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. Am J Gastroenterol. 94:1999;3131-3138.
28. So J.B.Y., Zeitels S.M., Rattner D.W. Outcome of atypical symptoms attributed to gastresophageal reflux disease treated by laparoscopic fundoplication. Surgery. 124:1998;28-32.
29. Neumann C.S., Iqbal T.H., Cooper B.T. Long term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment Pharmacol Ther. 9:1995;451-454.
30. Cooper B.T., Neumann C.S., Cox M.A., Iqbal T.H. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther. 12:1998;893-897.
31. Sampliner R.E. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol. 89:1994;1844-1848.
32. Malesci A., Savarino V., Zentilin P., et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc. 44:1996;700-705.
33. Wilkinson S.P., Biddlestone L., Gore S., Shepherd N.A. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily results of 5 years of continuous therapy . Aliment Pharmacol Ther. 13:1999;1205-1209.
34. Ouatu-Lascar R., Fitzgerald R.C., Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effect of acid suppression. Gastroenterology. 117:1999;327-335.
35. Peters F.T.M., Ganesh S., Kuipers E.J., et al. Endoscopic regression of Barrett's esophagus during omeprazole treatment a randomized double blind study . Gut. 45:1999;489-494.
36. Srinivasan R., Katz P.O., Castell D.O. Maximal acid reflux control for Barrett's oesophagus feasible and effective . Aliment Pharmacol Ther. 15:2001;519-524.
37. Lundell L., Miettinen P., Myrvold A.E., et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg. 192:2001;172-179. discussion 179-181.
38. Garnett W.R. Consideration for long-term use of proton pump inhibitor. Am J Health Syst Pharm. 55:1998;2268-2279.
39. Perdikis G., Hinder R.A., Lund R.J., et al. Laparoscopic Nissen fundoplication where do we stand? Surg Laparosc Endosc. 7:1997;17-21.
40. Spechler S.J., Lee E., Ahnen D., et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease follow-up of a randomized controlled trial . JAMA. 285:2001;2331-2338.